HSPG2 and cancer: If, although we have yet to obtain direct evidence, the PLC activity of PLCε is specifically required for the maintenance of cancer stemness, and also if the suppression of the activity of other PLCs with U73122 functions antagonistically against the suppression of stemness, novel PLC inhibitors that selectively inhibit PLCε may be promising therapeutic agents.